Treatment of psoriatic arthritis with Anti-cd70 antibody

a technology of anti-cd70 and psoriatic arthritis, which is applied in the field of treatment of psoriatic arthritis with anti-cd70 antibody, can solve the problems of significant adverse side effects and little treatment effect in established diseases

Inactive Publication Date: 2010-05-27
SEATTLE GENETICS INC
View PDF34 Cites 45 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, such treatment had little efficacy in established disease.
However, these agents are not specific and cause significant adverse side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of psoriatic arthritis with Anti-cd70 antibody
  • Treatment of psoriatic arthritis with Anti-cd70 antibody
  • Treatment of psoriatic arthritis with Anti-cd70 antibody

Examples

Experimental program
Comparison scheme
Effect test

example 1

Construction of Chimeric Anti-CD7 0 Antibody

[0196]To determine the cDNA sequences encoding the light (VL) and heavy (VH) chain variable regions of 1F6 and 2F2 mAb, total RNA was isolated from the 1F6 and 2F2 hybridomas using TRIzol® Reagent (Invitrogen, Carlsbad, Calif.) according to the manufacturer's instructions. Gene-specific primers mIgcK1: 5′-CTT CCA CTT GAC ATT GAT GTC TTT G-3′ (SEQ ID NO:41) and mIgGl: 5′-CAG GTC ACT GTC ACT GGC TCA G-3′ (SEQ ID NO:42) were applied to reverse transcribe the light chain variable (VL) and heavy chain variable (VH) first strand cDNAs from both RNA preparations, respectively. First strand cDNA reactions were run using the SuperScript™ First Strand Synthesis System for RT-PCR from Invitrogen. The VL and VH cDNAs were then poly-G tailed using terminal deoxynucleotidyl transferase (TdT) and the supplied TdT buffer, according to conditions specified by the manufacturer (Invitrogen). Poly-G tailed VL and VH first strand cDNAs were then subjected to P...

example 2

Chimeric 1F6 Mediates ADCC Against CD70+ Tumor Cell Lines

[0210]The ability of c1F6 to mediate ADCC against the CD70 cell lines WIL2-S, Caki-1 and 786-O was measured using a standard 51Cr release assay. Tumor cells were labeled for one hour with 100 μCi Na251CrO4, washed thoroughly to remove unincorporated radioisotope, then plated in a 96-well plate at a concentration of 5,000 cells per well. Antibodies c1F6, ml F6 or human Ig were added to appropriate wells at a final concentration of 1 μg / ml for 0.5 hours prior to the addition of effector PBMC. PBMC were adjusted to reflect an effector cell to target cell ratio of 30 CD16+ cells:1 target cell. After 4 hours incubation, the 51Cr released from lysed cells was measured and the percent specific lysis calculated as {(test sample cpm−spontaneous cpm)÷(total cpm−spontaneous cpm)}×100. Spontaneous release of isotope was determined from the supernatant of target cells incubated in medium alone. Total counts were determined from target cell...

example 3

Chimeric 1F6-Coated Target Cells Recognized by PBMC from Multiple Donors

[0211]Caki-1 renal cell carcinoma cells were labeled with Na251CrO4, treated with graded doses of c1F6, and then incubated with effector PBMC from two normal donors. Specific lysis was assessed after 4 hours incubation as described in Example 2. Donor 2051661 and ND016 efficiently lysed Caki-1 target cells treated with 1 or 0.1 μg / ml c1F6 (FIG. 6). Specific lysis decreased in an antibody dose-dependent manner thereafter, and was negligible when target cells were treated with 0.001 μg / ml c1F6. Target cells mixed with non-binding control Ig (hIg) were not lysed by PBMC from either donor.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment of psoriatic arthritis comprising administering the CD70 binding agents to a subject.

Description

CROSS REFERENCES TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. application Ser. No. 11 / 735,365 filed Apr. 13, 2007 (and allowed on Aug. 28, 2009), which application (1) claims the benefit of U.S. Provisional Patent Application No. 60 / 792,132, filed Apr. 13, 2006; and (2) is a continuation-in-part of U.S. application Ser. No. 11 / 251,173, filed Oct. 14, 2005, which claims the benefit of U.S. Provisional Patent Application No. 60 / 619,018, filed Oct. 15, 2004, and U.S. Provisional Application No. 60 / 645,355, filed Jan. 19, 2005, each of which applications is incorporated by reference herein in its entirety.REFERENCE TO A SEQUENCE LISTING[0002]This application includes a sequence listing provided in a text file entitled 826USSEQLIST.txt, having a size of 24,225 bytes and created on Nov. 16, 09, which is incorporated by reference in its entirety.BACKGROUND OF THE INVENTION[0003]CD70 is a member of the tumor necrosis factor (TNF) family of cell membrane-bound and se...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395
CPCA61K2039/505C07K16/2875C07K16/30C07K2317/77C07K2317/24C07K2317/732C07K2317/734C07K2317/21
Inventor LAW, CHE-LEUNGMCEARCHERN, JULIEWAHL, ALAN F.
Owner SEATTLE GENETICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap